Amanote Research
Register
Sign In
P53 Codon 72 Polymorphism Predicts the Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer
Clinical Cancer Research
- United States
doi 10.1158/1078-0432.ccr-05-0507
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Oncology
Date
October 15, 2005
Authors
Y. Xu
Publisher
American Association for Cancer Research (AACR)
Related search
HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients' Response to Neoadjuvant Chemotherapy
Frontiers in Immunology
Allergy
Immunology
Predictors of Recurrence in Breast Cancer Patients With a Pathologic Complete Response After Neoadjuvant Chemotherapy
British Journal of Cancer
Cancer Research
Oncology
P53 Codon 72 Polymorphism and Risk of Cervical Cancer
Biological Research
Genetics
Molecular Biology
Biochemistry
Biological Sciences
Medicine
Agricultural
P53 Codon 72 Polymorphism in Cervical Cancer Patients and Healthy Women From Poland.
Acta Biochimica Polonica
Biochemistry
Genetics
Molecular Biology
Genome-Wide DNA Methylation Signatures to Predict Pathologic Complete Response From Combined Neoadjuvant Chemotherapy With Bevacizumab in Breast Cancer
PLoS ONE
Multidisciplinary
CCR5 and P53 Codon 72 Gene Polymorphisms: Implications in Breast Cancer Development
International Journal of Molecular Medicine
Medicine
Genetics
Predicting Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer by Using MR Imaging and Quantitative1H MR Spectroscopy
Radiology
Nuclear Medicine
Radiology
Imaging
Accuracy of Ultrasonography and Mammography in Predicting Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer
American Journal of Surgery
Medicine
Surgery
MRP1 but Not MDR1 Is Associated With Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
Disease Markers
Biochemistry
Medicine
Clinical Biochemistry
Molecular Biology
Genetics
